Our Board of Directors
Russell G. Greig
Chairman of the Board
Russell G. Greig
Russell built a substantial career at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Over the last decade, Dr. Greig has served as Chairman and board member for a range of innovative biopharmaceutical companies in the US and in Europe including overseeing a number of successful exits.
Kenneth Chien
Co-founder of Moderna
Kenneth Chien
Professor Kenneth Chien is a self-investor to eTheRNA and has been an Advisor to EQT since 2020. Kenneth is a Co-Founder of Moderna Therapeutics, and has served as a senior consultant and advisory board member to several biotechnology and large pharmas, including Genentech, Roche, GSK, Wyeth, and Pfizer.
Marijn Dekkers
Representing Novalis LifeSciences
Marijn Dekkers
Marijn is founder and chairman of Novalis LifeSciences LLC, an investment and advisory firm for the Life Science industry that he founded in 2017.Dr. He served as CEO of Bayer AG in Germany and CEO of Thermo Fisher Scientific in USA. He started his career in 1985 as a research scientist at General Electric’s Corporate R&D Center in New York.
Bernard Sagaert
eTheRNA Interim CEO
Bernard Sagaert
Bernard Sagaert is an Industrial Pharmacist with extensive operational experience in the pharmaceutical and life sciences industry. He has expertise in pharmaceutical authorizations, inspections and manufacturing and has an extensive operational background, both in companies as consultant. He was a former QA & Supply Chain Director at Mylan in Belgium, and VP QA EMEAA at Sterigenics, a Sotera company.
Antonin (Tony) de Fougerolles
Board Member
Tony de Fougerolles
Antonin (Tony) de Fougerolles has an extensive background in mRNA and more specifically LNPs through his roles at Moderna and Alnylam. With nearly 25 years’ experience in building out drug pipelines, he has played a key role in successfully advancing 3 new drug modalities to market (mRNA, RNAi, single domain antibodies) and in helping build several multi-billion-dollar companies from start-up stage He is currently the CEO of Evox Therapeutics.
John de Koning
Board Member
John de Koning
John is a Partner at EQT Life Sciences, formerly LSP. He currently serves on the boards of eTheRNA, ONWARD Medical (Euronext: ONWD), Aelin Therapeutics, VarmX, Visus Therapeutics and Xilis. He also served on the boards of other companies, such as argenx (NASDAQ: ARGX), Merus (NASDAQ: MRUS), BMEYE (acquired by Edwards Lifesciences) and Prosensa (acquired by BioMarin).
Phil Chase
Board Member
Phil Chase
Philip is currently CEO of Adimab, a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies. Prior to Adimab, Mr. Chase held positions at various biotechnology companies, including serving as the General Counsel at Alnylam Pharmaceuticals and as Chief Corporate Counsel at Transkaryotic Therapies, Inc. He received his J.D. degree from Columbia University School of Law and his B.A. from Colby College.
Kenneth Wils
Board Member
Kenneth Wils
Kenneth is an all-round finance and venture capital professional with a passion for life sciences and healthcare. In 2007, he joined PMV, where he was primarily active as seed and early stage venture capital provider to innovative start-ups, with a focus on life sciences and healthcare. He also served as board member in several successful technology start-ups and funds.
Menu